Tirzepatide for Weight and Blood Sugar in Adults With Obesity or Type 2 Diabetes

Trial details

Who runs it

Las Rías Medical Center

Trial code

NCT07588438

Record updated

19 May 2026

Original description

This is a prospective cohort study evaluating the efficacy, safety, and tolerability of tirzepatide under real-world conditions in the Paraguayan population. The study includes two cohorts: Cohort 1 consists of adults with obesity (BMI ≥30 kg/m²) without type 2 diabetes mellitus (T2DM), and Cohort 2 consists of adults with T2DM with or without obesity. Each cohort will enroll 80 participants (160 total). All participants will receive tirzepatide as part of their standard clinical care and will be followed for 52 weeks with visits approximately every 6 weeks. Primary outcomes include percentage change in body weight from baseline at week 52 (Cohort 1) and change in HbA1c and body weight at week 52 (Cohort 2). Safety outcomes include adverse event rates. The study is conducted at Las Rias Medical Center, Asuncion, Paraguay, and has been approved by the CEI-INCAN Ethics Committee and authorized by DINAVISA.Read full original descriptionShow less

Prospective Cohort Study to Evaluate the Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Persons With Obesity Without Diabetes and Type 2 Diabetes Mellitus With or Without Obesity in Paraguay.

This is a prospective cohort study evaluating the efficacy, safety, and tolerability of tirzepatide under real-world conditions in the Paraguayan population. The study includes two cohorts: Cohort 1 consists of adults with obesity (BMI ≥30 kg/m²) without type 2 diabetes mellitus (T2DM), and Cohort 2 consists of adults with T2DM with or without obesity. Each cohort will enroll 80 participants (160 total). All participants will receive tirzepatide as part of their standard clinical care and will be followed for 52 weeks with visits approximately every 6 weeks. Primary outcomes include percentage change in body weight from baseline at week 52 (Cohort 1) and change in HbA1c and body weight at week 52 (Cohort 2). Safety outcomes include adverse event rates. The study is conducted at Las Rias Medical Center, Asuncion, Paraguay, and has been approved by the CEI-INCAN Ethics Committee and authorized by DINAVISA.

Inclusion: Age between 18 and 70 years at the time of informed consent; Stable residence in Paraguay for at least 12 months prior to screening; Ability to provide written informed consent and comply with all study procedures; Sufficient proficiency in the Spanish language to complete questionnaires and follow study instructions; Clinical stability, defined as the absence of hospitalization related to diabetes or obesity complications within 3 months prior to screening; Adequate renal function, defined as an estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73m² calculated using the CKD-EPI equation; For participants enrolled in the obesity cohort: clinical diagnosis of obesity with BMI ≥30 kg/m², no prior diagnosis of diabetes mellitus (HbA1c <6.5%), and at least one documented unsuccessful attempt at dietary weight-loss intervention within the previous 12 months; For participants enrolled in the type 2 diabetes mellitus (T2DM) cohort: established diagnosis of T2DM for at least 6 months prior to screening according to ADA 2025 criteria, HbA1c between 7.0% and 9.5% at screening confirmed at baseline, BMI ≥24 kg/m², and stable treatment on monotherapy or dual therapy with metformin, sulfonylureas, DPP-4 inhibitors, or SGLT-2 inhibitors for at least 3 months prior to screening.

Exclusion: History of diabetic ketoacidosis within 12 months prior to screening; Current or recent use (within 3 months prior to screening) of GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists; Current or prior use of insulin therapy for the management of diabetes; Major adverse cardiovascular event (MACE), including acute myocardial infarction, stroke, or hospitalization for heart failure within 6 months prior to screening; Active inflammatory bowel disease or prior bariatric surgery; Clinically significant diabetic gastroparesis or other gastrointestinal motility disorders that may interfere with the absorption of concomitant oral medications; Use of systemic corticosteroids for more than 14 consecutive days within 3 months prior to screening; Treatment with oral anti-obesity medications (including orlistat, phentermine, naltrexone/bupropion, or topiramate) within 3 months prior to screening; Participation in another clinical trial involving an investigational medicinal product within 30 days prior to screening; Uncontrolled major psychiatric disorders or history of suicide attempt within the previous 2 years; Diagnosis of type 1 diabetes mellitus or secondary causes of diabetes; Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; Heart failure classified as New York Heart Association (NYHA) Functional Class III or IV; Uncontrolled hypertension, defined as systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg despite optimal antihypertensive therapy; History of acute or chronic pancreatitis; Active malignancy or history of cancer within the previous 5 years, except for completely resected basal cell or squamous cell skin carcinoma; Moderate to advanced chronic kidney disease defined as eGFR <45 mL/min/1.73m² or requirement for dialysis; Active liver disease or transaminase levels (ALT/AST) greater than 3 times the upper limit of normal; Confirmed or suspected pregnancy, including positive serum beta-hCG test at screening, or active breastfeeding; Clinically significant untreated thyroid dysfunction, including hypothyroidism or hyperthyroidism; Intention to become pregnant during the study period; Women of childbearing potential unwilling to use effective contraceptive methods (hormonal, intrauterine, or dual-barrier) throughout the study and for 3 months after the final dose.

ClinicalTrials.gov NCT07588438